Search
T2EVOLVE: breakthrough alliance boosting Europe to the forefront of cancer immunotherapy
This press release is originally found here: http://prn. to/2YF7Js3
THE HAGUE, Netherlands, Feb. 3, 2021 /PRNewswire/ -- T2EVOLVE is a new breakthrough alliance of academic and industry leaders in cancer immunotherapy under the European Union's Innovative Medicines Initiative (IMI).
Urgent action needed to avoid widespread shortage of in-vitro diagnostic tests
In a new statement, BioMed Alliance highlights its increasing concern about the availability of In Vitro Diagnostic (IVD) testing devices in Europe.
Read moreEHA attends the EuNet-INNOCHRON Final Conference
The EuNet-INNOCHRON Final Conference, a significant event in the field of hematology, took place in Chania, Crete, Greece from April 4-6, 2024.
Read moreEHA Congratulates EHA Kick-Off Grant 2022 Winners
The Hague, December 8, 2022 – EHA Congratulates seven talented researchers in Hematology on their receipt of an EHA Kick-Off Grant 2022 after a rigorous selection process.
Read moreWithout access to treatment, can we truly innovate in rare diseases?
Interview with Giampaolo Merlini
There have been many developments on rare diseases since the EU Orphan Medicinal Products Regulation came into force in 2000. As the European Commission is evaluating its effectiveness, EHA discussed with Prof.
ASCERTAIN: EHA joins consortium aiming for better pricing and reimbursement models
November 28, 2022
EHA is a partner in the ASCERTAIN consortium which will develop models for the pricing, cost-benefit assessment, and reimbursement of innovative health technologies in Europe.
Lighting the Flame - Official launch
The European Hematology Association has now officially launched a new program, Lighting the Flame.
Read more